CD30-targeted cell therapy after stem cell transplant for Hodgkin lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new cell therapy (CD30 CAR T-cells) given after a stem cell transplant to treat Hodgkin lymphoma that has not responded well. It may help your body's immune cells fight the cancer more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 6 and 29 years old.
- Your Hodgkin lymphoma has relapsed (come back), been refractory (not gone away), or progressed (worsened) after treatment.
- Your cancer cells are CD30-positive (a specific protein on the cells).
- You are eligible for a stem cell transplant using your own stem cells.
- You have at least two of the listed risk factors (such as lower physical functioning, early relapse, or cancer spread outside lymph nodes).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using special immune cells (CAR-T cells) that are designed to find and attack lymphoma cells in people whose Hodgkin lymphoma has come back but is considered low risk. The study aims to see if this treatment works well and is safe for patients who have already responded to a first round of re-treatment.
This Phase 1 trial tests a new immune therapy made from your own immune cells (CAR T cells) for relapsed or refractory Hodgkin or non-Hodgkin lymphoma that has CD30 on the tumor. It aims to see if the treatment can shrink the lymphoma and find the safest dose.
This trial tests a lab-made immune cell therapy (CAR T) that targets CD30 on certain lymphoma cells. It may help people whose Hodgkin or non-Hodgkin lymphoma has come back or did not respond to usual treatments, including transplant and other medicines.
This trial tests a new type of immunotherapy called CD30 CAR-T cells for people with CD30-positive lymphoma that has come back or hasn't responded to other treatments. The treatment uses your own immune cells that are specially trained to find and kill lymphoma cells carrying the CD30 marker.
This trial tests a new type of immune cell therapy for CD30-positive lymphomas. The cells are made from donated blood and are designed to find and attack your cancer.
This trial tests a new treatment that uses your own immune cells, modified to find and attack cancer cells that have a protein called CD30 on them. It may be an option if your lymphoma has come back or hasn't improved with other treatments.
Hear when a new Classical Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.